Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Benralizumab in Japanese patients with severe asthma

Trial Profile

Efficacy and safety of Benralizumab in Japanese patients with severe asthma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 20 May 2020 Results(N=16), one year safety and efficacy of Benralizumab, presented at the 116th International Conference of the American Thoracic Society
  • 20 May 2020 Results (n=9) assessing long term efficacy and safety of bronchial thermoplasty treatment in severe Japanese asthmatic patients three year outcomes, presented at the 116th International Conference of the American Thoracic Society.
  • 19 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top